Immunomodulator agent-related lymphoproliferative disorders

Hiv-Related Lymphoproliferative Disorders

Lymphoproliferative disorders including non-Hodgkin lymphomas (NHL) are not uncommon neoplasms in patients infected with the human immunodeficiency virus (HIV). It has been established that HIV-infected individuals are more prone to develop certain lymphoproliferative disorders and lymphomas compared to non-infected individuals. The exact mechanisms underlying these associations is yet to be es...

Posttransplant Lymphoproliferative Disorders

Posttransplant lymphoproliferative disorders (PTLDs) are a group of diseases that range from benign polyclonal to malignant monoclonal lymphoid proliferations. They arise secondary to treatment with immunosuppressive drugs given to prevent transplant rejection. Three main pathologic subsets/stages of evolution are recognised: early, polymorphic, and monomorphic lesions. The pathogenesis of PTLD...

CD30+ lymphoproliferative disorders.

27. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann F, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95(10):1668-74. 28. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and M...

Posttransplant lymphoproliferative disorders.

Posttransplant lymphoproliferative disorder is a heterogeneous group of clonal hyperplasia/neoplasms that can range from benign to highly malignant lesions. Mortality rates can approach 60%. This entity has been on the rise for the last 2 decades with the advent of highly potent immunosuppressive agents. Epstein-Barr virus has shown to play a primary role in more than 90% of the cases. Although...

Posttransplant Lymphoproliferative Disorders